167 related articles for article (PubMed ID: 14504849)
1. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.
Sekino K; Kubota T; Okada Y; Yamada Y; Yamamoto K; Horiuchi R; Kimura K; Iga T
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):589-92. PubMed ID: 14504849
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.
Yasar U; Forslund-Bergengren C; Tybring G; Dorado P; Llerena A; Sjöqvist F; Eliasson E; Dahl ML
Clin Pharmacol Ther; 2002 Jan; 71(1):89-98. PubMed ID: 11823761
[TBL] [Abstract][Full Text] [Related]
3. Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.
Li Z; Wang G; Wang LS; Zhang W; Tan ZR; Fan L; Chen BL; Li Q; Liu J; Tu JH; Hu DL; Liu ZQ; Zhou HH
Xenobiotica; 2009 Oct; 39(10):788-93. PubMed ID: 19604036
[TBL] [Abstract][Full Text] [Related]
4. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo.
Wennerholm A; Nordmark A; Pihlsgård M; Mahindi M; Bertilsson L; Gustafsson LL
Eur J Clin Pharmacol; 2006 Jul; 62(7):539-46. PubMed ID: 16783563
[TBL] [Abstract][Full Text] [Related]
5. CYP2C9 genetic variants and losartan oxidation in a Turkish population.
Babaoglu MO; Yasar U; Sandberg M; Eliasson E; Dahl ML; Kayaalp SO; Bozkurt A
Eur J Clin Pharmacol; 2004 Jul; 60(5):337-42. PubMed ID: 15197523
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model.
Lankford SM; Plummer D; Hellyer P; Christ DD; Bai SA
J Cardiovasc Pharmacol; 1997 Nov; 30(5):583-90. PubMed ID: 9388040
[TBL] [Abstract][Full Text] [Related]
7. Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan.
Wong PC; Christ DD; Wong YN; Lam GN
Pharmacology; 1996 Jan; 52(1):25-9. PubMed ID: 8966199
[TBL] [Abstract][Full Text] [Related]
8. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.
Lee CR; Pieper JA; Hinderliter AL; Blaisdell JA; Goldstein JA
Pharmacotherapy; 2003 Jun; 23(6):720-5. PubMed ID: 12820813
[TBL] [Abstract][Full Text] [Related]
9. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.
Kaukonen KM; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Feb; 53(6):445-9. PubMed ID: 9551703
[TBL] [Abstract][Full Text] [Related]
10. Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes.
Dorado P; Machín E; de Andrés F; Naranjo ME; Peñas-Lledó EM; Llerena A;
Drug Metabol Drug Interact; 2012; 27(4):217-33. PubMed ID: 23093260
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.
Bae JW; Choi CI; Lee HI; Lee YJ; Jang CG; Lee SY
Int J Clin Pharmacol Ther; 2012 Sep; 50(9):683-9. PubMed ID: 22735459
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus.
Moon CH; Lee HJ; Jung YS; Lee SH; Baik EJ
Res Commun Mol Pathol Pharmacol; 1998 Aug; 101(2):147-58. PubMed ID: 9821211
[TBL] [Abstract][Full Text] [Related]
13. Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats.
Yang SH; Cho YA; Choi JS
Acta Pharmacol Sin; 2011 Jul; 32(7):967-72. PubMed ID: 21666702
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans.
Lo MW; Goldberg MR; McCrea JB; Lu H; Furtek CI; Bjornsson TD
Clin Pharmacol Ther; 1995 Dec; 58(6):641-9. PubMed ID: 8529329
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between warfarin dosing and activity of CYP2C9 assessed by the content of losartan and its metabolite E-3174 in the urine of patients with mechanical prosthetic heart valves].
Arslanbekova SM; Sychev DA; Kazakov RE; Smirnov VV; Kuznetsova EV; Golukhova EZ
Kardiologiia; 2013; 53(12):21-4. PubMed ID: 24800477
[TBL] [Abstract][Full Text] [Related]
16. Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.
Bae JW; Choi CI; Kim MJ; Oh DH; Keum SK; Park JI; Kim BH; Bang HK; Oh SG; Kang BS; Park HJ; Kim HD; Ha JH; Shin HJ; Kim YH; Na HS; Chung MW; Jang CG; Lee SY
Acta Pharmacol Sin; 2011 Oct; 32(10):1303-8. PubMed ID: 21841812
[TBL] [Abstract][Full Text] [Related]
17. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.
Joy MS; Dornbrook-Lavender K; Blaisdell J; Hilliard T; Boyette T; Hu Y; Hogan SL; Candiani C; Falk RJ; Goldstein JA
Eur J Clin Pharmacol; 2009 Sep; 65(9):947-53. PubMed ID: 19669737
[TBL] [Abstract][Full Text] [Related]
18. Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity.
Yasar U; Dahl ML; Christensen M; Eliasson E
Br J Clin Pharmacol; 2002 Aug; 54(2):183-5. PubMed ID: 12207639
[No Abstract] [Full Text] [Related]
19. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers.
Han Y; Guo D; Chen Y; Chen Y; Tan ZR; Zhou HH
Eur J Clin Pharmacol; 2009 Jun; 65(6):585-91. PubMed ID: 19221727
[TBL] [Abstract][Full Text] [Related]
20. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.
Lee CR; Pieper JA; Frye RF; Hinderliter AL; Blaisdell JA; Goldstein JA
J Clin Pharmacol; 2003 Jan; 43(1):84-91. PubMed ID: 12520632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
